Kymriah (Tisagenlecleucel)

Kymriah is indicated for CD19‑positive B‑cell malignancies that have relapsed or are refractory to standard therapy.

• Relapsed or refractory B‑cell acute lymphoblastic leukemia (ALL) in patients up to 25 years: provides targeted cellular therapy to achieve remission.
• Relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) in adults: offers a CAR‑T option when conventional treatments have failed.
• Other CD19‑positive B‑cell lymphomas: delivers autologous CAR‑T cells to induce tumor cell lysis.

• Kymriah uses autologous T cells harvested from the patient, which are genetically engineered to express a chimeric antigen receptor (CAR) that specifically binds CD19 on malignant B cells. After infusion, the modified cells recognize CD19‑expressing cells, become activated, proliferate, and mediate cytotoxic killing of the target cancer cells.

Kymriah may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Cytokine release syndrome (fever, hypotension, tachycardia, and flu‑like symptoms)
• Neurologic toxicities (headache, confusion, tremor, or mild seizures)
• Fatigue and generalized malaise lasting several days
• Nausea, vomiting, and loss of appetite

Serious or Rare Side Effects

• Severe cytokine release syndrome requiring intensive care and vasopressor support
• Immune effector cell‑associated neurotoxicity syndrome (ICANS) with severe seizures or cerebral edema
• Prolonged cytopenias leading to heightened infection risk and possible transfusion dependence
• B‑cell aplasia causing hypogammaglobulinemia and recurrent infections

Before initiating Kymriah, clinicians should observe several precautionary measures to ensure patient safety.

• Patient selection: confirm CD19‑positive disease and meet eligibility criteria for CAR‑T therapy.
• Baseline organ function: evaluate cardiac, hepatic and renal parameters before infusion.
• Monitoring for CRS: observe vital signs, laboratory markers, and intervene promptly if syndrome develops.
• Neurotoxicity surveillance: conduct regular neurologic examinations during the first weeks post‑infusion.
• Pregnancy and lactation: avoid use; safety in pregnant or breastfeeding women is not established.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Kymriah can interact with other therapies, requiring careful management.

Major Interactions (Avoid)

• Live vaccines: may cause uncontrolled infection due to immunosuppression from CAR‑T therapy.
• High‑dose corticosteroids given concurrently: can suppress CAR‑T cell expansion and reduce efficacy.
• Additional cellular therapies: may interfere with T‑cell function and increase safety risks.

Moderate Interactions (Monitor Closely)

• Antimicrobial prophylaxis agents: adjust dosing as cytopenias may heighten infection susceptibility.
• Anticoagulants: monitor bleeding risk when thrombocytopenia occurs after infusion.
• Cytokine‑targeting agents (e.g., tocilizumab) used for CRS management: balance therapeutic benefit against infection risk.
• Other immunomodulators: observe for additive immune‑related adverse events and possible reduced CAR‑T activity.